Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Bela-maf, carfilzomib, len, and dex for RRMM shows ORR 89.5%, 78.9% VGPR or better, MRD negative in all CRs; 24-month PFS and OS 74.3% and 85.1%, respectively; keratopathy in 94.7%, mostly grade 1-2, reversible, manageable.”
Title: Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma
Authors: Shebli Atrash, James Symanowski, Myra Robinson, Cecilia Flynn, Sarah Norek, Robin Cox, Monica Plott, Kelly Bumgarner, Darynne Rhinehardt, Xhevahire Begic, Ami Ndiaye, Jordan Robinson, Reed Friend, Barry Paul, Cindy Varga, Christopher Ferreri, Mauricio Pineda-Roman, David Foureau, Manisha Bhutani, Peter Voorhees
You can read the Full Article in Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
